Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer. A proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 403-409

  Paik, Jin Ho ^a   Choi, Chang Min ^b   Kim, Hyojin ^a   Jang, Se Jin ^b   Choe, Gheeyoung ^a   Kim, Dong Kwan ^b   Kim, Hwa Jung ^c   Yoon, Hoil ^a   Lee, Choon Taek ^a   Jheon, Sanghoon ^a   Choe, Ji Young ^a   Chung, Jin Haeng ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

ALK; Fluorescence in situ hybridization; Immunohistochemistry; Non small cell lung cancer; Prognosis

Indexed keywords

ONCOPROTEIN; PROTEIN ALK; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALGORITHM; ALK GENE; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; EGFR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENDER; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SMOKING; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84860500563     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.11.008     Document Type: Article

References (24)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Ettinger D.S, Bepler G., Bueno R., Chang A., Chang J.Y., Chirieac L.R., et al. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006, 4:548-582.
3. Detterbeck F.C. Lumping, splitting, and sorting. J Thorac Oncol 2007, 2:581-582.
4. Greene F.L., Sobin L.H. The TNM system: our language for cancer care. J Surg Oncol 2002, 80:119-120.
5. Kerr K.M. Pulmonary adenocarcinomas: classification and reporting. Histopathology 2009, 54:12-27.
6. Travis W.D. Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee. Histopathology 2009, 54:3-11.
7. Horn L., Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009, 27:4232-4235.
8. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
9. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
10. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
11. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
12. Kim H.J., Yoo S.B., Choe J.Y., Paik J.H., Nitta H., Zhang W., et al. Detection of ALK gene rearrangement in non-small-cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011, 6:1359-1366.
13. Paik J.H., Choe G., Kim H., Choe J.Y., Lee H.J., Lee C.T., et al. Screening of ALK rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011, 6:466-472.
14. Martelli M.P., Sozzi G., Hernandez L., Pettirossi V., Navarro A., Conte D., et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009, 174:661-670.
15. Inamura K., Takeuchi K., Togashi Y., Hatano S., Ninomiya H., Motoi N., et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009, 22:508-515.
16. Shaw A.T., Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011, 17:2081-2086.
17. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
18. Lee H.J., Xu X., Choe G., Chung D.H., Seo J.W., Lee J.H., et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 2010, 68:375-382.
19. Yoo S.B., Lee H.J., Park J.O., Choe G., Chung D.H., Seo J.W., et al. Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: a comparison with fluorescence in situ hybridization study. Lung Cancer 2010, 67:301-305.
20. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
21. Chung J.H., Choe G., Jheon S., Sung S.W., Kim T.J., Lee K.W., et al. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol 2009, 4:1490-1495.
22. Rodig S.J., Mino-Kenudson M., Dacic S., Yeap B.Y., Shaw A., Barletta J.A., et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15:5216-5223.
23. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-4283.
24. Wong D.W., Leung E.L., So K.K., Tam I.Y., Sihoe A.D., Cheng L.C., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115:1723-1733.